Matthew Mc Neill
About Matthew Mc Neill
Matthew Mc Neill is a Principal Scientist in Computational Biology at Sana Biotechnology, Inc., with extensive experience in bioinformatics and a strong background in programming. He has previously held positions at Integrated DNA Technologies and the University of Illinois at Urbana-Champaign, and he holds a PhD in Neuroscience from the University of Iowa.
Current Role at Sana Biotechnology
Matthew Mc Neill currently serves as Principal Scientist in Computational Biology at Sana Biotechnology, Inc. He has held this position since 2022. In this role, he applies his expertise in computational biology to advance the company's research and development efforts in biotechnology.
Previous Experience at Integrated DNA Technologies
Prior to his current role, Mc Neill worked at Integrated DNA Technologies for a total of four years in various capacities. He served as Manager of Bioinformatics from 2021 to 2022, and as Bioinformatics Senior Staff Scientist from 2018 to 2021. Earlier, he was a Staff Scientist from 2015 to 2018. His experience at Integrated DNA Technologies focused on bioinformatics and data analysis in the biotechnology sector.
Academic Background and Education
Matthew Mc Neill earned his PhD in Neuroscience from the University of Iowa, where he studied from 2004 to 2009. He also holds a Bachelor of Science (B.S.) degree in Zoology from Miami University, completed from 2000 to 2004. His academic training laid the foundation for his career in computational biology and bioinformatics.
Research Experience at University of Illinois
Mc Neill worked as a Post Doctoral Researcher at the University of Illinois at Urbana-Champaign from 2010 to 2014. During this four-year period, he engaged in advanced research that contributed to his expertise in computational biology and related fields.
Technical Skills and Expertise
Matthew Mc Neill possesses strong programming skills in Python and R, which are essential for data analysis in computational biology. He has expertise in CRISPR technology and next-generation sequencing (NGS) data analysis, making him a valuable asset in the biotechnology industry.